


# Molecular foundations of drug-receptor interaction

P.M. Dean



# *Molecular foundations of drug-receptor interaction*


---

P.M.DEAN

*Department of Pharmacology, University of Cambridge*



Y075166



CAMBRIDGE UNIVERSITY PRESS

*Cambridge*

*London New York New Rochelle*

*Melbourne Sydney*

Published by the Press Syndicate of the University of Cambridge  
The Pitt Building, Trumpington Street, Cambridge CB2 1RP  
32 East 57th Street, New York, NY 10022, USA  
10 Stamford Road, Oakleigh, Melbourne 3166, Australia

© Cambridge University Press 1987

First published 1987

Printed in Great Britain by University Press, Cambridge

*British Library Cataloguing in Publication Data*

Dean, P. M.

Molecular foundations of drug-receptor  
interaction.

1. Drugs – Structure-activity relationships

I. Title

615'.7 RM301.42

*Library of Congress Cataloguing in Publication Data*

Dean, P. M. (Philip Michael), 1944–

Molecular foundations of drug-receptor interaction.

Bibliography:

Includes indexes.

1. Molecular pharmacology. 2. Drug receptors.

I. Title.

RM301.65.D43 1987 615'.7 86-28381

ISBN 0 521 30255 2

MP

## PREFACE

---

In the beginning, before *Molecular Foundations* was formed, a meeting with the Biological Sciences Editor of Cambridge University Press was held to discuss possible approaches to the subject. The editor explained that she did not require either another standard text on molecular pharmacology or a catalogue of facts and chemical formulae compiled into a massive scientific 'Bible'.

'We are in the computer age now and it is time there was a book dealing with molecular pharmacology to reflect this', she finally stated.

The principal objective of this book, therefore, has been to draw together those strands of research, carried out since 1970, that widen our understanding of the molecular details of drug-receptor interaction. Hopefully, the book is more substantial than an introduction, but it is not an exhaustive treatment of the subject. Only what I consider to be primary material is surveyed here; much detailed background literature has not been handled. Technical items can be found by returning to the original papers cited in the references. Part of this material has been used in Part 2 of the Natural Sciences Tripos (Pharmacology) and so could be useful as an advanced undergraduate textbook. However, most of the book is of more specialist interest and should appeal to research scientists working in the wider field of biomolecular interactions.

One of the major difficulties in writing a book to the brief that it must be modern and up to date, lies in the limitation that the research one has to consider is of necessity novel, speculative and largely untested. The writer has to run the risk, if he includes contemporary material, of drawing attention to work which may, at a later date, prove to be unreliable. Nevertheless, research is a restless occupation and there is much to be said for propagating the stimulus of new ideas to provoke further thought, so that out of the melting pot of controversy these ideas can be refined to stand the test of time.

The main thrust of this book is to shift the emphasis away from phenomenological experiments of pharmacology to molecular theory, that is, to move to the place where we can ask questions that are too difficult, or impossible, to answer by conventional experiments. At this level of questioning we can only construct hypotheses based on molecular theory and provide computational simulations to test our ideas. For example, we cannot measure the molecular electrostatic potential in the cleft of a drug binding site but, given the atomic charges obtained from a quantum chemistry calculation, we can compute the potential and make some deductions from those computations about drug action and specificity. How could we test our prediction of the value of the potential? In this brave new world of computational chemistry there are many pitfalls to trip the unwary. Rash generalizations from limited data can be very tempting when most calculations deal only with simulating the *in vacuo* state and neglect the solvent environment. It is easy to get drunk on enthusiasm about new developments, to be blind to mistakes and to be hypnotized by clever speculation.

The underlying assumption of this book is that it is possible to treat drug-receptor interaction purely as a chemical problem. This problem lies at the heart of pharmacology, but many pharmacologists seem unaware that it is surreptitiously being stolen from them by scientists from other specialist disciplines. A careful perusal of the references at the end of this book reveals that only a small number of pharmacological journals are quoted. Many of the important recent advances are to be found in literature that few pharmacologists would regularly scan. This is due, in part, to the fact that the overwhelming mass of research in pharmacology is, naturally, concerned with how particular drugs act on the body's physiological systems; there seems to be little commitment to understanding what is happening at the molecular level. Current awareness of recent developments in drug-receptor interaction is essential if the molecular nature of the problem is to remain accessible to us as the theoretical basis of pharmacology.

This book is limited to one small step in the chain of events of drug action. Only the very first stage is considered, namely the initial interaction between the drug molecule and its receptor site to form a molecular complex. Biochemical and biophysical consequences that follow from this step are not described since very little is, as yet, clearly understood about them. The initial events can loosely be described as molecular recognition. If recognition can be understood in the precise language of intermolecular forces, there will undoubtedly be important applications of molecular theory to the design of new drug molecules. This theme of recognition

forms a constant undercurrent throughout the book and its link to the rational design of novel ligands is frequently alluded to.

One of the great advantages that an author has when commissioned to write a book is that he is forced to sit down and read through the earlier literature to trace the historical development of his subject. It seems to me that one paper is pre-eminent in laying the molecular foundations of drug-receptor interaction. Sir Arnold Burgen's (1966) concise essay on 'The drug-receptor complex' is almost a manifesto for subsequent investigations, the results of which are now outlined here. What is surprising is that his paper was written before the application of computational chemistry to biomolecular interactions. These new techniques have, since then, simply filled in some of the details of the overall plan.

My own research interests are heavily invested in three chapters written here and so reflect the importance that I personally attach to those areas. Close involvement with one part of a topic may have led me to overemphasize it with respect to other related viewpoints. It is extremely difficult, when one is intimately involved with a subject, to stand at some vantage point and view the whole field impartially; thus I am aware of my own particular perspectives.

Chapter 1 outlines the historical development of theories about drug-receptor interaction beginning with the birth of the receptor concept by Langley and Ehrlich. Major steps in understanding drug action are highlighted over a period of nearly 100 years. This chapter will be familiar to classically trained pharmacologists, but I believe there is little mileage left in this approach which is essentially one of empirically fitting equations to gross measurements of tissue responses. The rest of the book concentrates on molecular details. There is a strong emphasis throughout the text on the need to understand and manipulate three-dimensional molecular structure. Chapter 2 provides some basic mathematical and crystallographic methods for handling molecular architectures. Work in the early 1980s on molecular databases is also outlined to provide the reader with ready access to these new and important facilities. Structural geometry gives rise to different spatial dispositions of intermolecular forces. Chapter 3 examines these forces and deals in detail with some of those that are believed to be crucial in drug-receptor interaction. Quantum chemistry is not dealt with in this book; an excellent treatment of it, and its application to molecular pharmacology, can be found elsewhere (Richards, 1983). If molecular shapes are to be handled by computer programs, methods must be developed to characterize and handle shape in any form (chapter 4). Only certain portions of the molecular receptor are concerned

with ligand binding. Different ways to examine these sites are explored in chapter 5. Most computational models for drug-receptor interaction ignore the solvent environment. This neglect is a substantial defect in current models. The behaviour of solvent molecules over small intermolecular distances is not well understood. What inroads have been made into this complex problem in the physical sciences (chapter 6)? The docking manoeuvre of a drug molecule into its receptor site is illustrated in chapter 7 where emphasis is placed on electrostatic interactions. Practical applications of computational chemistry to the rational design of new drugs are outlined in chapter 8. The final chapter attempts to predict the major avenues along which drug-receptor interaction will progress. Three important developments are already surfacing: protein engineering offers the pharmacologist the ability to re-design the receptor; knowledge engineering draws together key strands from artificial intelligence that are making it possible for new comprehensive and automated techniques to emerge for drug design; new computer hardware will, if the fifth generation project is successful, provide sufficient computing power to make molecular simulations significantly more complex and bring the research on drug-receptor interaction nearer to completeness.

I would like to acknowledge with gratitude the encouragement and financial support given to me over many years by the Wellcome Trust. Without the Trust's generosity it would not have been possible for me to pursue a research career largely unfettered by a heavy academic teaching load. Thanks go to colleagues in the department, and elsewhere in Cambridge, for providing stimulus and a lively environment for the exchange of new ideas. Lastly, but not least, I am indebted to Diana for patiently deciphering my writing for input to the word-processor and then nit-picking through the manuscript to remove many grammatical obscurities.

Cambridge, May 1986.

P. M. Dean

## ACKNOWLEDGEMENTS

---

I would like to thank the following for permission to publish copyright material: The American Chemical Society and the authors for permission to reproduce tables 1 and 2 from *Biochemistry* (1980) **19**, 3732; tables 2 and 3 from *Biochemistry* (1980) **19**, 3723; table 3 from *Biochemistry* **23**, 4733; figures 2b, 3b and tables 4, 5 and 6 from *Journal of the American Chemical Society* (1979) **101**, 825; Macmillan Press and the authors for permission to reproduce tables 1 and 2 from *The British Journal of Pharmacology* (1979) **65**, 535; table 1 from *Nature* (1985) **313**, 364; Oxford University Press and authors for permission to reproduce table 1 from *X-ray Crystallography and Drug Action* (1984) edited by A. Horn and C. de Ranter, p. 169; International Union of Crystallography and the authors for permission to reproduce tables 3, 4b and 4c from *Acta Crystallographica* (1978) **B34**, 2534; table 2 from *Acta Crystallographica* (1982) **B38**, 2516; Pharmaceutical Society of Japan and the authors for permission to reproduce figures 2a, 2b, 3a and 3b from the *Chemical and Pharmaceutical Bulletin* (1984) **32**, 3313; Cold Spring Harbor Symposia and the author for permission to reproduce table 1 from *Cold Spring Harbor Symposium* (1983) **47**, 251; American Society of Biological Chemists and authors for permission to reproduce figure 6 and table 3 from the *Journal of Biological Chemistry* (1982) **257**, 13650; figure 2 and tables 2, 3 and 4 from the *Journal of Biological Chemistry* (1982) **257**, 13663; Academic Press and authors for permission to reproduce table 3 from the *Journal of Molecular Biology* (1983) **168**, 621; table 2 from the *Journal of Molecular Biology* (1982) **157**, 105.

# CONTENTS

---

<i>Preface</i>	xi
<b>1 The development of theories about drug-receptor interaction</b>	<b>1</b>
1.1 The concept of receptors	2
1.1.1. J. N. Langley	2
1.1.2. P. Ehrlich	3
1.1.3. Langley again	6
1.2 Early chemical theories of drug-receptor interaction	7
1.2.1. A. V. Hill	7
1.2.2. A. J. Clark and occupation theory	8
1.3 Antagonism	11
1.4 Biological activity	13
1.4.1. Intrinsic activity	13
1.4.2. Efficacy and stimulus	15
1.4.3. Spare receptors	18
1.4.4. Intrinsic efficacy	19
1.5 Stimulus-response relationships	20
1.5.1. Stimulus chains and functional interactions	20
1.5.2. Transducer models for receptor-effector coupling	22
1.5.3. Transducer coupling between receptors and ion channels	25
1.5.4. Transducer coupling and functional antagonism	27
1.5.5. Ion gating	27
1.6 Cooperativity	29
1.6.1. Negative cooperativity	30
1.6.2. Positive cooperativity at the nicotinic acetylcholine receptor (nAChR)	30
1.7 Molecular mechanisms in drug-receptor interaction	31
1.7.1. Molecular factors that determine the formation of the drug-receptor complex	32
1.8 Drug-receptor interaction and computational chemistry	33

<b>2</b>	<b>Structural geometry of molecules</b>	35
2.1	Why do we need precise geometrical information?	35
2.2	Analytic geometry and matrix transformation	36
2.2.1.	Molecular coordinate systems	36
2.2.2.	Elementary relationships in analytic geometry	38
2.2.3.	Elementary matrix transformation	40
2.3	Crystallographic terms	42
2.3.1.	The unit cell	42
2.3.2.	Crystal and orthogonal axes	45
2.3.3.	Structure determination	47
2.3.4.	Neutron diffraction	51
2.4	The use of crystal data	51
2.5	Databases of molecular structures	57
2.5.1.	Cambridge Structural Database (CSD)	58
2.5.2.	Computer analysis of data files of molecular geometry	59
2.5.3.	The Brookhaven Protein Data Bank	64
2.6	Protein structures	66
2.6.1.	Chemical composition	66
2.6.2.	Protein crystals for x-ray diffraction	67
2.6.3.	Electron density maps	67
2.6.4.	Structure refinement	69
<b>3</b>	<b>Intra- and intermolecular forces</b>	70
3.1	Methods to calculate different forces	73
3.1.1.	The electron distribution	73
3.1.2.	Electrostatic energy	76
3.1.3.	Induction energy	78
3.1.4.	Dispersion energy	79
3.1.5.	Short-range energies	80
3.1.6.	Interaction energy calculations	81
3.1.7.	Atom-atom pair-potentials	81
3.2	Molecular dynamics	83
3.3	Intramolecular forces	87
3.4	Hydrogen bonds in drug-receptor interaction	91
3.4.1.	Geometries of hydrogen bonds	92
3.5	Molecular electrostatic potentials	96
3.5.1.	Calculation of the electrostatic potential	96
3.5.2.	Display of molecular electrostatic potentials	97
3.5.3.	The use of molecular electrostatic potentials	99
3.6	Hydrophobic interactions	103
3.6.1.	Evaluation of hydrophobicity	104
3.6.2.	Molecular shape and hydrophobic interactions	106
<b>4</b>	<b>Characterization of molecular shape</b>	109
4.1	Electron density distribution and shape	109

4.2	Distance matrices (DMs) and data manipulation	111
4.2.1	Animated DMs in molecular dynamics	112
4.2.2	Molecular superposition	115
4.3	Molecular surfaces	118
4.3.1	Geometrical complementarity between molecular surfaces	121
4.4	Intramolecular flexibility and conformation	122
4.4.1	Conformational energy computations	123
4.4.2	Conformation of small peptide units	126
4.4.3	Graphical representation of multiple torsion angles	128
4.5	Macromolecular receptor structures	130
4.5.1	Classification of protein structure	130
4.5.2	Protein structure correlations with function	134
4.5.3	Nucleic acid structure and conformation	134
4.6	Prediction of polypeptide structure from amino acid sequence	139
4.7	Dynamic conformational changes in proteins	142
4.7.1	Atom mobility in proteins	145
4.8	Software systems for shape display	147
4.8.1	Molecular structure	147
4.8.2	Accessible surface representation	148
4.8.3	Graphical display of quantum-mechanical properties on molecular surfaces	149
<b>5</b>	<b>Ligand-binding sites</b>	<b>150</b>
5.1	Identification of receptors	150
5.2	Identification of binding sites for drug molecules	153
5.2.1	DHFR	153
5.2.2	The active site	157
5.2.3	Site-points for binding NADPH	158
5.2.4	Site-points for methotrexate	161
5.2.5	Substrate binding	162
5.2.6	A structural mechanism for catalysis	162
5.3	Geometrical searching for binding sites	165
5.4	Identification of latent binding sites	169
5.5	Subsets of site-points	176
5.5.1	Coenzyme binding to DHFR	177
5.5.2	Inhibitor binding to DHFR	179
5.6	Topographical mapping of ligand-binding sites by inference methods	185
<b>6</b>	<b>The importance of solvent in drug-receptor interactions</b>	<b>188</b>
6.1	The structure of water	189
6.1.1	Liquid water	189
6.1.2	Water structure at a macromolecular surface	191

6.2	Organized water in crystal structures	193
6.2.1.	Water surrounding small molecules	194
6.2.2.	Water at macromolecular surfaces	197
6.2.3.	Water surrounding drug-receptor complexes	201
6.3	Simulation of the solvent environment	205
6.3.1.	The supermolecule approach to hydration	206
6.3.2.	Water isoenergy contour maps	208
6.3.3.	Monte Carlo simulations of hydration	211
6.3.4.	Simulation of solvation by molecular dynamics	216
6.4	Hydrophilicity and hydrophobicity	221
6.4.1.	Hydrophathy	221
6.4.2.	Hydrophathy and tertiary structure of proteins	223
6.4.3.	Hydrophobic moments	225
6.5	The effect of water on intermolecular interactions	227
6.5.1.	Dielectric theory	228
6.5.2.	Water as a dielectric medium	230
6.5.3.	Ion interactions in water	231
7	<b>Ligand docking at a binding site</b>	236
7.1	Mechanical flexibility and the formation of intercalative sites	237
7.2	Molecular energy changes in the unstacking of adjacent base pairs	241
7.2.1.	Interactions between the backbone and base pairs	241
7.2.2.	Base-pair interactions in an electric field	243
7.3	Molecular electrostatic potentials	247
7.3.1.	Calculation of electronic charge distributions	247
7.3.2.	Molecular electrostatic potential surrounding (dC-dG)·(dC-dG)	251
7.3.3.	Molecular electrostatic potentials surrounding polynucleotides	252
7.3.4.	Electrostatic complementarity	254
7.3.5.	Perturbation of the receptor electrostatic potential by a drug molecule	258
7.4	Receptor-induced ligand orientation	258
7.4.1.	Roll rotation	260
7.4.2.	Yaw rotation	261
7.4.3.	Pitch rotation	262
7.5	Electric fields and ligand orientation	263
7.5.1.	The electric field	263
7.5.2.	Direction fields surrounding base pairs of nucleic acids	264
7.5.3.	Direction fields along the helix axis of nucleic acid	266
7.5.4.	Ligand orientation in the receptor's electric field	270
7.6	Stability of the drug-receptor complex	275
7.6.1.	Interaction energies for drug-dinucleotide complexes	276

7.6.2. Drug-induced conformational changes in the dinucleotide receptor	278
7.7 Intramolecular changes during docking	279
7.7.1. Modification of the electron distribution in the drug molecule	280
7.7.2. Changes in orbital energies in the drug molecule	281
7.7.3. Intramolecular changes in substrate docking at an active site	283
7.8 Software for docking interactions	285
<b>8 Ligand design techniques</b>	287
8.1 The problem of design	287
8.1.1. The biochemical lead	288
8.1.2. Combinatorial modifications to a lead structure	289
8.1.3. Combinatorial reduction by feature selection	290
8.1.4. Emerging pathways for rational design of ligands	291
8.2 Ligand design to fit a known structural site	292
8.2.1. The diphosphoglycerate binding site on haemoglobin	292
8.2.2. Construction of a ligand to fit the DPG site	294
8.2.3. Testing the putative ligands for biological activity	295
8.2.4. Ligand binding at genetically modified sites	298
8.3 Ligand design in the absence of information about site structure	300
8.3.1. Chemometrics	300
8.3.2. Multivariate analysis	301
8.3.3. Multivariate regression analysis	303
8.3.4. Principal component analysis	303
8.3.5. Descriptors of molecular structure	306
8.3.6. Molecular descriptors in linear free enthalpy relationships	308
8.3.7. Optimization of molecular design from chemometric data	313
8.4 Computer-aided ligand design	316
8.4.1. Representation of receptor structure	317
8.4.2. Construction of a hypothetical ligand	318
8.4.3. Molecular graphical displays	321
8.4.4. Computer-aided ligand construction	323
8.4.5. Computer-aided QSAR	323
8.4.6. Inhibitors of angiotensin converting enzyme (ACE)	324
<b>9 Future studies in drug-receptor interaction</b>	328
9.1 Protein engineering	328
9.1.1. Site-directed mutagenesis	328
9.1.2. Protein engineering and macromolecular recognition	331
9.1.3. Modifications to the acetylcholine receptor by site-directed mutagenesis	333
9.1.4. Redesigning binding sites for structure-function studies	334

9.2	Knowledge engineering	337
9.2.1.	Drug design using computer-aided synthesis	340
9.2.2.	Synthesis planning	341
9.2.3.	Logic and heuristics applied to synthetic analysis (LHASA)	341
9.2.4.	Artificial intelligence in QSAR	344
9.2.5.	Representation of molecular structure by computer codes	345
9.2.6.	Automatic selection of structural descriptors for QSAR	346
9.2.7.	Automatic allocation of hydrogen-bonding site-points to macromolecular surfaces	348
9.3	Computations for drug-receptor interaction by supercomputers	348
9.3.1.	Parallel processing	349
9.3.2.	Distributed array processors (DAP)	350
9.3.3.	Molecular dynamics calculations on DAPs	351
	Postscript	353
	References	355
	Subject index	372
	Author index	377

---

## *The development of theories about drug-receptor interaction*

The reading of seminal papers in any scientific discipline, in the cool silence of a good library, is akin to the experience of visiting the cellars of a well-established wine-merchant. The pleasure of tasting the classed growths of Bordeaux in sequence through the years is punctuated at definite and widely recognized intervals by the great vintages. At these points in history the wines are remarkable for their intensity, complexity and finish; they manage to stand the test of time without deterioration. So with drug-receptor interaction, there are extraordinary periods of intellectual growth within the discipline, landmarks in time where developments have held together despite the changing tides of fashion.

For the pharmacologist, drug-receptor interaction is the very heart of his subject; yet despite the centrality of this theory to the practical development of new drugs, surprisingly little is known about the process. Only in the last decade or so, have we been able to characterize the molecular structures of a few receptors. Naturally, the pharmacologist's understanding has lagged behind the evolution of chemical theories of molecular reactions. Only with the advent of high-speed computers has it been possible to apply the rigours of computational chemistry to molecular biological problems. Recent progress in these different research areas has led to a flurry of new work; chemical theories inaccessible to experiment can be evaluated by careful computational simulation. This novel work forms the subject matter of the book. However, we must begin by placing these new ideas within an historical perspective. Ideas do not just happen in isolation, they emerge from a fertile milieu through a process of accretion. Ehrlich described this process as 'a host of individual facts which, being stored at a subconscious level, lead one to take involuntarily the right direction'. (Dale, 1956).

Inevitably, whenever a review of drug-receptor interaction is

contemplated the discussion revolves around the axis of Paul Ehrlich. His astonishing abilities, sheer hard work, and prophetic vision have contributed more to this subject than that of any other worker. In a key paper on structure-activity relationships which Ehrlich published in 1902 he expressed his hopes, his fears and his rationale in these words: 'Hence the expectation to be able to construct new drugs of predetermined action on the basis of theoretical conceptions will probably have to be deferred for a long time. To the initiate, the lack of sufficient positive knowledge is revealed by the inactivity which now characterizes a field once entered upon with so much promise. The innumerable drugs which have overwhelmed medicine in the past few years, of which only a few are of any value and thus denote any real progress, have sufficed speedily to allay the original enthusiasm. A feeling of indifference has thus been engendered, which is constantly being increased by the advertisements which are daily becoming more and more evident. Apart from these evils, however, this line of study is at present suffering especially from two other evils:

- (1) The habit, when a drug has been partially accepted, of immediately following it with a dozen rivals of similar composition, and,
- (2) The exclusive preference given to drugs acting purely symptomatically, which are not true curative agents.

A change for the better will occur only when purely biological points of view are adopted, ie if the initiative is transferred from the chemical to the biological laboratory. As physicians we must cease to be content with the auxiliary role of advisers in these important questions. In this subject, our very own since time immemorial, we must insist on taking first place. Now is the time that we must turn to more general, biological conceptions, and it is therefore the duty of everyone to contribute his brick to the construction of this new theory.' The cornerstone was destined to be laid by Ehrlich with his notion of receptors.

## 1.1 The concept of receptors

### 1.1.1 J. N. Langley

The notion of specific receptors for drug molecules or natural neurotransmitters developed slowly over the course of about 20 years. Two strands in the research can be detected. J. N. Langley, working in Cambridge under the influence of Michael Foster, began his studies of the nervous system linked initially to the mechanism of secretion. His early studies were on the action of the recently discovered cholinomimetic compound jaborandi. The drug stimulated salivary secretion and could be antagonized by atropine (Langley, 1873, 1878). In the discussion of his

1878 paper Langley speculated 'Until some definite conclusion as to the point of action of the poisons is arrived at it is not worth while to theorize much on their mode of action: but we may, I think, without much rashness, assume that there is some substance or substances in the nerve endings or gland cells with which both atropine and pilocarpin are capable of forming compounds. On this assumption then the atropine or pilocarpin compounds are formed according to some law of which their relative mass and chemical affinity for the substance are factors. In the analogous case with inorganic substances, other things being equal, these are the sole factors. To take the simplest case, if  $a$  and  $b$  are both able to form, with  $y$ , the compounds  $ay$  and  $by$ , then  $ay$  and  $by$  are both formed, the quantity of  $ay$  and  $by$  depending on the relative masses of  $a$  and  $b$  present and their relative chemical affinity to  $y$ .' Receptors, antagonism, chemical affinity, drug-receptor complex, all the ingredients for receptor theory are here, but they lay dormant for many years. Meanwhile, the results of these initial findings led to a number of papers on antagonism of various poisons by physiologically active alkaloids (Langley, 1880; Langley & Dickinson, 1890a, b). This research pathway focused on the nerve endings in ganglia, the neuromuscular junction and neural control of secretion.

### 1.1.2 P. Ehrlich

Ehrlich's contribution forms the second strand and was independent of Langley's work; it approached the notion of receptors from a different direction. An early training in the chemistry of dyestuffs provided Ehrlich with a great facility for research in staining biological tissues and he made numerous important contributions to histology. One observation in histology that fascinated Ehrlich was the fact that staining could be specific for a particular tissue. Furthermore, he noted that substances which stain neuronal tissues are lipid soluble. If the lipid solubility of the chromophore group is changed, for example by making a sulphonic acid derivative, although the colour remains the dye is not taken up by the tissue and the biological material is not stained. This simple observation led to the idea that different chemical structures could show different biological distributions and the distribution of a chromophore could be changed by modifying the molecular structure. The possibility that dyestuffs could combine with specific parts of biological tissue was not appreciated for many years because there were many competing theories about the staining process.

Ehrlich's work with dyestuffs had bearing on another idea that was popular at the end of the nineteenth century; this was the emerging notion of affinity. It had been observed that many of the biologically active